Avior Wealth Management
JANX icon

Avior Wealth Management’s Janux Therapeutics JANX Stock Holding History

Avior Wealth Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-98
Closed -$5.25K – 1557
2024
Q4 		$5.25K Sell
98
-13
-12% -$688 ﹤0.01% 1841
2024
Q3 		$5.04K Hold
111
– – ﹤0.01% 1780
2024
Q2 		$4.65K Sell
111
-3
-3% -$141 ﹤0.01% 1744
2024
Q1 		$4.29K Sell
114
-129
-53% -$2.81K ﹤0.01% 2116
2023
Q4 		$2.61K Buy
+243
New +$2.1K ﹤0.01% 1271

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Avior Wealth Management's JANX Position: Q1 2025 in Review

Avior Wealth Management sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 98 shares — an estimated $5.25K sold.

Avior Wealth Management first reported a position in JANX in Q4 2023 and held it in 5 quarters. The position peaked at $5.25K in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Avior Wealth Management reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 98 Janux Therapeutics shares in Q1 2025, an estimated $5.25K.
  • Avior Wealth Management first reported a position in Janux Therapeutics in Q4 2023 and held it in 5 quarters.
  • Avior Wealth Management's Janux Therapeutics position peaked at $5.25K in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.